Therapy resistance is the major hurdle to the successful treatment of human malignancies and preempts responsiveness to a broad range of therapeutic strategies including chemotherapies, targeted therapies, radiation, immune checkpoint inhibitors, surgery, and hormonal therapy.
Using different drugs that act on different targets in combinational approaches exhibits increased anti-tumor activity and decreases the likelihood that resistant cancer cells will arise. However, de novo and acquired resistance to combination therapies have been widely described, especially in patients with metastatic disease, dampening the initial efficacy and resulting in disease relapse.
Therefore, there is a pressing need to fully understand the molecular and cellular mechanisms that drive cancer therapy resistance to improve current therapies and open new windows of opportunities for novel and more effective future cancer treatments.
This Research Topic aims to outline the most recent findings on the molecular and cellular mediators involved in therapy failure in human malignancies and new therapeutic approaches to overcome drug resistance. We welcome Original Research Articles, Review Articles And Perspective Articles focused on, but not limited to, the following topics:
- Mechanisms involved in resistance to single-agents treatment and/or combinational therapeutic approaches
- Novel approaches to bypass drug resistance in tumor cells
- Role of intra- and inter-patients variability in cancer therapy resistance
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Therapy resistance is the major hurdle to the successful treatment of human malignancies and preempts responsiveness to a broad range of therapeutic strategies including chemotherapies, targeted therapies, radiation, immune checkpoint inhibitors, surgery, and hormonal therapy.
Using different drugs that act on different targets in combinational approaches exhibits increased anti-tumor activity and decreases the likelihood that resistant cancer cells will arise. However, de novo and acquired resistance to combination therapies have been widely described, especially in patients with metastatic disease, dampening the initial efficacy and resulting in disease relapse.
Therefore, there is a pressing need to fully understand the molecular and cellular mechanisms that drive cancer therapy resistance to improve current therapies and open new windows of opportunities for novel and more effective future cancer treatments.
This Research Topic aims to outline the most recent findings on the molecular and cellular mediators involved in therapy failure in human malignancies and new therapeutic approaches to overcome drug resistance. We welcome Original Research Articles, Review Articles And Perspective Articles focused on, but not limited to, the following topics:
- Mechanisms involved in resistance to single-agents treatment and/or combinational therapeutic approaches
- Novel approaches to bypass drug resistance in tumor cells
- Role of intra- and inter-patients variability in cancer therapy resistance
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
